COMPARISON
Semaglutide vs Triptorelin
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Semaglutide is authorised or registered in 10 and Triptorelin in 10 of the 10 registers read. Semaglutide: highest phase Phase 4 (after approval). Triptorelin: highest phase Phase 4 (after approval). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Semaglutide | Triptorelin | |
|---|---|---|
| Registered trials differs | 861 clinicaltrials.gov · 2026-10-03 | 317 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Trelstar openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-08-31 |
| EU authorised on differs | 2018-02-08 ema · 2026-10-03 | Not checked no record of "authorisedOn" for triptorelin |
| ATC code differs | A10BJ06 ema · 2026-10-03 | Not checked no record of "atcCode" for triptorelin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Semaglutide | placebo | Triptorelin | placebo |
|---|---|---|---|---|
| Nausea | 19.5% | 4.5% | - | - |
| COVID-19 | 17.0% | 17.8% | - | - |
| Diarrhoea | 11.8% | 4.5% | - | - |
| Constipation | 8.9% | 2.8% | - | - |
| Vomiting | 8.6% | 1.6% | - | - |
| Nasopharyngitis | 7.5% | 6.1% | - | - |
| Decreased appetite | 6.3% | 1.3% | - | - |
| Dyspepsia | 5.3% | 1.2% | - | - |
| Headache | 4.0% | 2.1% | - | - |
| Upper respiratory tract infection | 2.7% | 1.9% | - | - |
Trial register Semaglutide: 50 placebo-controlled trials; Triptorelin: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Semaglutide side effects · Triptorelin side effects
LEGAL STATUS
Approval in each country read
| Country | Semaglutide | Triptorelin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT07242534 | Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. RECRUITING · updated 2026-01-21 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.